These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28386063)

  • 1. Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility.
    Mantere T; Tervasmäki A; Nurmi A; Rapakko K; Kauppila S; Tang J; Schleutker J; Kallioniemi A; Hartikainen JM; Mannermaa A; Nieminen P; Hanhisalo R; Lehto S; Suvanto M; Grip M; Jukkola-Vuorinen A; Tengström M; Auvinen P; Kvist A; Borg Å; Blomqvist C; Aittomäki K; Greenberg RA; Winqvist R; Nevanlinna H; Pylkäs K
    Sci Rep; 2017 Apr; 7(1):681. PubMed ID: 28386063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rare missense mutations in RECQL and POLG associate with inherited predisposition to breast cancer.
    Tervasmäki A; Mantere T; Hartikainen JM; Kauppila S; Lee HM; Koivuluoma S; Grip M; Karihtala P; Jukkola-Vuorinen A; Mannermaa A; Winqvist R; Pylkäs K
    Int J Cancer; 2018 Jun; 142(11):2286-2292. PubMed ID: 29341116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer.
    Lewis AG; Flanagan J; Marsh A; Pupo GM; Mann G; Spurdle AB; Lindeman GJ; Visvader JE; Brown MA; Chenevix-Trench G;
    Breast Cancer Res; 2005; 7(6):R1005-16. PubMed ID: 16280053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes.
    Slavin TP; Neuhausen SL; Nehoray B; Niell-Swiller M; Solomon I; Rybak C; Blazer K; Adamson A; Yang K; Sand S; Guerrero-Llamas N; Castillo D; Herzog J; Wu X; Tao S; Raja S; Chung V; Singh G; Nadesan S; Brown S; Cruz-Correa M; Petersen GM; Weitzel J;
    Fam Cancer; 2018 Apr; 17(2):235-245. PubMed ID: 28687971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
    Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
    BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.
    Seal S; Barfoot R; Jayatilake H; Smith P; Renwick A; Bascombe L; McGuffog L; Evans DG; Eccles D; Easton DF; Stratton MR; Rahman N;
    Cancer Res; 2003 Dec; 63(24):8596-9. PubMed ID: 14695169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer.
    Paulo P; Maia S; Pinto C; Pinto P; Monteiro A; Peixoto A; Teixeira MR
    PLoS Genet; 2018 Apr; 14(4):e1007355. PubMed ID: 29659569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk.
    Vagena A; Papamentzelopoulou M; Kalfakakou D; Kollia P; Papadimitriou C; Psyrri A; Apostolou P; Fountzilas G; Konstantopoulou I; Yannoukakos D; Fostira F
    J Hum Genet; 2019 Aug; 64(8):767-773. PubMed ID: 31089269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein-truncating variants in moderate-risk breast cancer susceptibility genes: a meta-analysis of high-risk case-control screening studies.
    Aloraifi F; McCartan D; McDevitt T; Green AJ; Bracken A; Geraghty J
    Cancer Genet; 2015 Sep; 208(9):455-63. PubMed ID: 26250988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finnish Fanconi anemia mutations and hereditary predisposition to breast and prostate cancer.
    Mantere T; Haanpää M; Hanenberg H; Schleutker J; Kallioniemi A; Kähkönen M; Parto K; Avela K; Aittomäki K; von Koskull H; Hartikainen JM; Kosma VM; Laasanen SL; Mannermaa A; Pylkäs K; Winqvist R
    Clin Genet; 2015 Jul; 88(1):68-73. PubMed ID: 24989076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Single-Nucleotide Polymorphisms in Monoubiquitinated FANCD2-DNA Damage Repair Pathway Genes With Breast Cancer in the Chinese Population.
    Chen FY; Wang H; Li H; Hu XL; Dai X; Wang SM; Yan GJ; Jiang PL; Hu YP; Huang J; Tang LL
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818819841. PubMed ID: 30799775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
    García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
    Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
    Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability.
    Heikkinen K; Rapakko K; Karppinen SM; Erkko H; Knuutila S; Lundán T; Mannermaa A; Børresen-Dale AL; Borg A; Barkardottir RB; Petrini J; Winqvist R
    Carcinogenesis; 2006 Aug; 27(8):1593-9. PubMed ID: 16474176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer.
    Pylkäs K; Tommiska J; Syrjäkoski K; Kere J; Gatei M; Waddell N; Allinen M; Karppinen SM; Rapakko K; Kääriäinen H; Aittomäki K; Blomqvist C; Mustonen A; Holli K; Khanna KK; Kallioniemi OP; Nevanlinna H; Winqvist R
    Carcinogenesis; 2007 May; 28(5):1040-5. PubMed ID: 17166884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families.
    Solyom S; Pylkäs K; Winqvist R
    Fam Cancer; 2010 Dec; 9(4):537-40. PubMed ID: 20567916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.
    Vuorela M; Pylkäs K; Hartikainen JM; Sundfeldt K; Lindblom A; von Wachenfeldt Wäppling A; Haanpää M; Puistola U; Rosengren A; Anttila M; Kosma VM; Mannermaa A; Winqvist R
    Breast Cancer Res Treat; 2011 Dec; 130(3):1003-10. PubMed ID: 21750962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
    Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
    Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.
    Silvestri V; Zelli V; Valentini V; Rizzolo P; Navazio AS; Coppa A; Agata S; Oliani C; Barana D; Castrignanò T; Viel A; Russo A; Tibiletti MG; Zanna I; Masala G; Cortesi L; Manoukian S; Azzollini J; Peissel B; Bonanni B; Peterlongo P; Radice P; Palli D; Giannini G; Chillemi G; Montagna M; Ottini L
    Cancer; 2017 Jan; 123(2):210-218. PubMed ID: 27648926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.